RayKnowChina Research Map
Shortlist

WenzhouWenzhou Medical University

First Affiliated Hospital of Wenzhou Medical University

温州医科大学附属第一医院

Listed for 23 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Wenzhou Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
  3. Hepatocellular carcinoma肝细胞癌96 papers led2 open trials led
  4. Stomach cancer胃癌55 papers led3 open trials led
  5. Osteosarcoma骨肉瘤1 paper led
  6. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
  7. Neuroblastoma神经母细胞瘤2 papers led
  8. Multiple myeloma多发性骨髓瘤6 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  10. Beta thalassaemiaβ 地中海贫血2 papers led
  11. Haemophilia A血友病 A0 papers led
  12. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病5 papers led
  13. Myasthenia gravis重症肌无力4 papers led
  14. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  15. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  16. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  17. Behçet disease白塞病1 paper led
  18. IgA nephropathyIgA 肾病6 papers led
  19. Gaucher disease戈谢病0 papers led
  20. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  21. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  22. Congenital diaphragmatic hernia先天性膈疝0 papers led
  23. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 442025

1 hospital in Wenzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05126160

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy
Departments in papersRadiation oncology
Papers it led8
  1. Optimal combination treatment for Locally Advanced Nasopharyngeal Carcinoma: A systematic review and Bayesian Network Meta-Analysis.2025American journal of otolaryngology
  2. The clinical value of FAPI PET/CT in delineating target volumes for nasopharyngeal carcinoma.2025European journal of nuclear medicine and molecular imagingFree full text
  3. Radiomics-guided generative adversarial network for automatic primary target volume segmentation for nasopharyngeal carcinoma using computed tomography images.2025Medical physics
  4. Deep learning dosiomics for the pretreatment prediction of radiation dermatitis in nasopharyngeal carcinoma patients treated with radiotherapy.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Automatic detection and recognition of nasopharynx gross tumour volume (GTVnx) by deep learning for nasopharyngeal cancer radiotherapy through magnetic resonance imaging.2023Radiation oncology (London, England)Free full text
  6. A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.2023Radiation oncology (London, England)Free full text
  7. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review.2021American journal of otolaryngology
  8. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
All its trials on ClinicalTrials.gov, any status1
  1. Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160Study siteStart 2021-11
More papers found outside PubMed (not counted)5
  1. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncologyarticle
  2. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncologyconference-abstract
  3. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncologyconference-abstract
  4. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  5. miRNAs Associated with Nasopharyngeal Carcinoma: New Prognostic Biomarkers and Therapeutic Targets2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

3 hospitals in Wenzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIRadiotherapyMolecular markers & genomics
Departments in papersGastroenterology / hepatologyRadiation oncology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 96 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
96
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 202020212022: 171720222023: 191920232024: 222220242025: 16162025

2 hospitals in Wenzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07381634

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  2. Recruiting
    Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07495735

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  3. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  4. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  5. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  6. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led96
  1. Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.2026European radiology
  2. Development of a new nomogram for predicting recurrence in HCC with MVI following curative hepatectomy.2026International journal of surgery (London, England)
  3. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study.2025BMC cancerFree full text
  4. Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics.2025BMC cancerFree full text
  5. Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B.2025BMC cancerFree full text
  6. Explainable machine learning model for predicting the transarterial chemoembolization response and subtypes of hepatocellular carcinoma patients.2025BMC gastroenterologyFree full text
  7. Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN.2025Cell death & diseaseFree full text
  8. METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression.2025Cell death & diseaseFree full text
  9. Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic.2025Cellular signalling
  10. Melatonin reverses lenvatinib resistance in HCC by regulating the ATF4-NRF1 pathway mediated by ceramide synthase 6.2025Cellular signalling
  11. Demethoxycurcumin induces metabolic crisis and ATF4/ATF3/CHOP-dependent cell death in hepatocellular carcinoma.2025Chemico-biological interactions
  12. Integrated GMPS and RAMP3 as a signature to predict prognosis and immune heterogeneity in hepatocellular carcinoma.2025Gene
  13. Role of alphaII-spectrin and XPF interaction in Hepatocellular carcinoma.2025Gene
  14. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma in patients with decompensated cirrhosis.2025HPB : the official journal of the International Hepato Pancreato Biliary Association
  15. Visualization of protrusion-localized STAT3 mRNA using a self-powered lipidic nanoflare for predicting hepatocellular carcinoma metastasis.2025Mikrochimica actaFree full text
  16. Formosanin C induces autophagy-mediated cell death in hepatocellular carcinoma through activating DUSP1/AMPK/ULK1/Beclin1 signaling pathway.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  17. Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.2025Scientific reportsFree full text
  18. Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis.2025The Journal of biological chemistryFree full text
  19. Carfilzomib activates ER stress and JNK/p38 MAPK signaling to promote apoptosis in hepatocellular carcinoma cells.2024Acta biochimica et biophysica SinicaFree full text
  20. Does an Aspirin a Day Take the MASLD Away?2024Advances in therapy
  21. Knockdown of ribosome RNA processing protein 15 suppresses migration of hepatocellular carcinoma through inhibiting PATZ1-associated LAMC2/FAK pathway.2024BMC cancerFree full text
  22. Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score.2024BMC cancerFree full text
  23. A novel prognostic signature and therapy guidance for hepatocellular carcinoma based on STEAP family.2024BMC medical genomicsFree full text
  24. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.2024Biochemical and biophysical research communications
  25. Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA.2024Biosensors & bioelectronics
  26. Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasFree full text
  27. The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  28. Gut Microbiota as Mediator and Moderator Between Hepatitis B Virus and Hepatocellular Carcinoma: A Prospective Study.2024Cancer medicineFree full text
  29. ZNF300 promotes proliferation and migration of hepatocellular carcinoma by upregulating c-MYC gene expression.2024Clinics and research in hepatology and gastroenterology
  30. Suppressing MTERF3 inhibits proliferation of human hepatocellular carcinoma via ROS-mediated p38 MAPK activation.2024Communications biologyFree full text
  31. Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma.2024Computers in biology and medicine
  32. The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma.2024Critical reviews in oncology/hematology
  33. Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study.2024Diabetes, obesity & metabolism
  34. Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib.2024Gut microbesFree full text
  35. Single-cell-based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.2024Hepatology (Baltimore, Md.)
  36. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.2024Journal of internal medicineFree full text
  37. In vitro vascularized liver tumor model based on a microfluidic inverse opal scaffold for immune cell recruitment investigation.2024Lab on a chip
  38. ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway.2024Molecular carcinogenesis
  39. Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC.2024Oncogene
  40. Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression.2024Technology in cancer research & treatmentFree full text
  41. Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma.2023BMC cancerFree full text
  42. Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma.2023BMC cancerFree full text
  43. A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma.2023BMC medical genomicsFree full text
  44. Matrix metalloproteinase-21 promotes metastasis via increasing the recruitment and M2 polarization of macrophages in HCC.2023Cancer scienceFree full text
  45. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.2023Cancer scienceFree full text
  46. lncRNA SNHG9 enhances liver cancer stem cell self-renewal and tumorigenicity by negatively regulating PTEN expression via recruiting EZH2.2023Cell and tissue research
  47. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.2023Clinical and translational medicineFree full text
  48. Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  49. Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation.2023Clinical radiology
  50. Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.2023Current drug targets
  51. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.2023Free radical biology & medicine
  52. The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  53. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.2023Gut microbesFree full text
  54. The utility of Vision Transformer in preoperatively predicting microvascular invasion status of hepatocellular carcinoma.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  55. Reflections on prediction of microvascular invasion in hepatocellular carcinoma by pathology images.2023Hepatology international
  56. Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-κB pathway.2023International journal of biological sciencesFree full text
  57. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  58. Rational Design of Gd-DOTA-Type Contrast Agents for Hepatobiliary Magnetic Resonance Imaging.2023Journal of medicinal chemistry
  59. Characterization of neutrophil extracellular traps related gene pair for predicting prognosis in hepatocellular carcinoma.2023The journal of gene medicine
  60. Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma.2022Annals of surgical oncology
  61. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.2022BMC cancerFree full text
  62. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.2022BMC cancerFree full text
  63. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.2022Cardiovascular and interventional radiology
  64. Role of ferroptosis in gastrointestinal tumors: From mechanisms to therapies.2022Cell biology international
  65. LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination.2022Cell death & diseaseFree full text
  66. The Expressions and Functions of lncRNA Related to m6A in Hepatocellular Carcinoma from a Bioinformatics Analysis.2022Computational and mathematical methods in medicineFree full text
  67. Identification and Validation of Hub Genes Predicting Prognosis of Hepatocellular Carcinoma.2022Digestive surgery
  68. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.2022European radiology
  69. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.2022Frontiers in immunologyFree full text
  70. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.2022Hepatology international
  71. Impact of sarcopenia on outcomes of patients undergoing liver resection for hepatocellular carcinoma.2022Journal of cachexia, sarcopenia and muscleFree full text
  72. CAFs-derived SCUBE1 promotes malignancy and stemness through the Shh/Gli1 pathway in hepatocellular carcinoma.2022Journal of translational medicineFree full text
  73. miRNA-432 and SLC38A1 as Predictors of Hepatocellular Carcinoma Complicated with Alcoholic Steatohepatitis.2022Oxidative medicine and cellular longevityFree full text
  74. Signature Construction and Molecular Subtype Identification Based on Pyroptosis-Related Genes for Better Prediction of Prognosis in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  75. Construction of a Metabolism-Related Long Non-Coding RNAs-Based Risk Score Model of Hepatocellular Carcinoma for Prognosis and Personalized Treatment Prediction.2022Pathology oncology research : PORFree full text
  76. Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.2022Updates in surgery
  77. Liposomes co-loaded with ursolic acid and ginsenoside Rg3 in the treatment of hepatocellular carcinoma.2021Acta biochimica Polonica
  78. A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma.2021AgingFree full text
  79. Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma.2021AgingFree full text
  80. Letter: Hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma.2021Alimentary pharmacology & therapeutics
  81. LncRNA AIRN influences the proliferation and apoptosis of hepatocellular carcinoma cells by regulating STAT1 ubiquitination.2021Archives of pharmacal research
  82. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy.2021BMC surgeryFree full text
  83. Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  84. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.2021BioengineeredFree full text
  85. A signature of 13 autophagy‑related gene pairs predicts prognosis in hepatocellular carcinoma.2021BioengineeredFree full text
  86. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.2021Bioscience reportsFree full text
  87. The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma: a meta-analysis.2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasFree full text
  88. FGF21 in obesity and cancer: New insights.2021Cancer lettersFree full text
  89. BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism.2021Cell death & diseaseFree full text
  90. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.2021Chinese medical journalFree full text
  91. Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.2021Frontiers in public healthFree full text
  92. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma.2021Journal of cellular and molecular medicineFree full text
  93. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis.2021Journal of cellular and molecular medicineFree full text
  94. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.2021Journal of experimental & clinical cancer research : CRRCTFree full text
  95. Identification of Biomarkers Based on Bioinformatics Analysis: The Expression of Ubiquitin-Conjugating Enzyme E2T (UBE2T) in the Carcinogenesis and Progression of Hepatocellular Carcinoma.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  96. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.2021Molecular medicine (Cambridge, Mass.)Free full text
All its trials on ClinicalTrials.gov, any status16
  1. Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular CarcinomaRecruitingNCT07495735Lead sponsorStart 2026-03
  2. The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related ToxicitiesRecruitingNCT07381634Lead sponsorPhase 2Start 2026-04
  3. Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic TherapiesStatus unknownNCT05448222Lead sponsorStart 2022-07
  4. Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic TreatmentsStatus unknownNCT05443217Lead sponsorStart 2022-06
  5. Relationship Between Liver Cancer and SarcopeniaStatus unknownNCT05339919Lead sponsorStart 2020-05
  6. Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)Status unknownNCT05543304Lead sponsorStart 2018-12
  7. Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsStatus unknownNCT03302403Lead (inferred)N/AStart 2017-12
  8. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  9. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  10. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  11. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  12. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT06310590Study sitePhase 1Start 2023-08
  13. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  14. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  15. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07
  16. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 55 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
55
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 111120212022: 121220222023: 3320232024: 141420242025: 14142025

3 hospitals in Wenzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
    Phase
    N/A
    Started
    2025-11
    Registry
    NCT07586384

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  2. Not yet recruiting
    Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-09
    Registry
    NCT07394205

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  3. Not yet recruiting
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07828899

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou

  4. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  5. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryNutrition & recoveryImaging & AI
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineRadiation oncology
Papers it led55
  1. CT-based delta-radiomics nomogram to assess tumor regression grade in locally advanced gastric cancer patients following neoadjuvant chemotherapy.2026Abdominal radiology (New York)
  2. Research advancements and evaluation of multifactor-induced murine models for gastric cancer.2025Animal models and experimental medicineFree full text
  3. CD2AP shapes a stromal reduced tumor microenvironment and contributes to immunotherapy in gastric cancer.2025BMC cancerFree full text
  4. Sarcopenia defined by the global leadership initiative in sarcopenia (GLIS) consensus predicts adverse postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: analysis from a prospective cohort study.2025BMC cancerFree full text
  5. Heterogeneity of T cells regulates tumor immunity mediated by Helicobacter pylori infection in gastric cancer.2025BMC cancerFree full text
  6. Machine learning assisted radiomics in predicting postoperative occurrence of deep venous thrombosis in patients with gastric cancer.2025BMC cancerFree full text
  7. Multi-regional feature integration on enhanced CT for lymph node metastasis prediction in gastric cancer: a novel radiomics approach.2025BMC medical imagingFree full text
  8. SNRPB promotes gastric cancer progression by regulating aberrant splicing of PUF60.2025Cell death & diseaseFree full text
  9. Stair climbing outperforms gait speed in predicting postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: A prospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. Muscle-specific strength is an alternative to muscle mass and grip strength for predicting outcomes in patients with gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Perioperative body composition changes and their clinical implications in patients with gastric cancer undergoing radical gastric cancer surgery: a prospective cohort study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  12. Human cytomegalovirus tegument protein UL23 promotes gastric cancer immune evasion by facilitating PD-L1 transcription.2025Molecular medicine (Cambridge, Mass.)Free full text
  13. Risk factors and prognostic impact of low physical performance in elderly patients undergoing radical gastrectomy for gastric cancer.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  14. Body composition analysis using CT at three aspects of the lumbar third vertebra and its impact on the diagnosis of sarcopenia.2025World journal of surgical oncologyFree full text
  15. NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer.2025eLifeFree full text
  16. Effects of esketamine on postoperative fatigue syndrome in patients after laparoscopic resection of gastric carcinoma: a randomized controlled trial.2024BMC anesthesiologyRCTFree full text
  17. Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.2024BMC cancerFree full text
  18. Development and validation of a machine learning-based 18F-fluorodeoxyglucose PET/CT radiomics signature for predicting gastric cancer survival.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  19. An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study.2024Cancer medicineFree full text
  20. Computed tomography-based radiomics nomogram for predicting therapeutic response to neoadjuvant chemotherapy in locally advanced gastric cancer : A scale for treatment predicting.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  21. Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer.2024Clinical nutrition (Edinburgh, Scotland)
  22. Utilizing machine learning to integrate single-cell and bulk RNA sequencing data for constructing and validating a novel cell adhesion molecules related prognostic model in gastric cancer.2024Computers in biology and medicine
  23. Enhanced PSO feature selection with Runge-Kutta and Gaussian sampling for precise gastric cancer recurrence prediction.2024Computers in biology and medicine
  24. Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  25. Prognostic value and association of the age-adjusted Charlson Comorbidity Index with sarcopenia within patients with gastric cancer after radical resection.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  26. Correlation Between Basal Metabolic Rate and Clinical Outcomes in Gastric Cancer Patients: A Retrospective Study.2024Journal of investigative surgery : the official journal of the Academy of Surgical Research
  27. Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for Gastric Cancer.2024Journal of translational medicineFree full text
  28. Muscle attenuation, not skeletal muscle index, is an independent prognostic factor for survival in gastric cancer patients with overweight and obesity.2024Nutrition (Burbank, Los Angeles County, Calif.)
  29. Predictive nomogram for lymph node metastasis and survival in gastric cancer using contrast-enhanced computed tomography-based radiomics: a retrospective study.2024PeerJFree full text
  30. miR-325-3p Reduces Proliferation and Promotes Apoptosis of Gastric Cancer Cells by Inhibiting Human Antigen R.2023Canadian journal of gastroenterology & hepatologyFree full text
  31. Lactate Dehydrogenase and Risk of Readmission with Gastric Cancer: A Propensity Score Matching Analysis.2023Journal of investigative surgery : the official journal of the Academy of Surgical Research
  32. Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics.2023La Radiologia medicaRCT
  33. Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study.2022Annals of surgical oncology
  34. ASO Author Reflections: Comparison of Sarcopenia and Cachexia for Their Prognostic Value in Gastric Cancer Patients at Different TNM Stages After Gastrectomy.2022Annals of surgical oncology
  35. Integration of clinical and transcriptomics reveals programming of the lipid metabolism in gastric cancer.2022BMC cancerFree full text
  36. NF-κB-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer.2022BioMed research internationalFree full text
  37. Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.2022Cellular oncology (Dordrecht, Netherlands)Free full text
  38. Bioinformatics Analysis Revealing the Correlation between NF-κB Signaling Pathway and Immune Infiltration in Gastric Cancer.2022Computational and mathematical methods in medicineFree full text
  39. Global leadership initiative in malnutrition (GLIM) criteria using hand-grip strength adequately predicts postoperative complications and long-term survival in patients underwent radical gastrectomy for gastric cancer.2022European journal of clinical nutrition
  40. Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo.2022European journal of pharmacology
  41. Impact of malnutrition diagnosed using Global Leadership Initiative on Malnutrition criteria on clinical outcomes of patients with gastric cancer.2022JPEN. Journal of parenteral and enteral nutrition
  42. Effect of Short-Term Preoperative Parenteral Nutrition Support for Gastric Cancer Patients with Sarcopenia: a Propensity Score Matching Analysis.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  43. Association of Sarcopenia and Low Nutritional Status with Unplanned Hospital Readmission after Radical Gastrectomy in Patients with Gastric Cancer: A Case-Control Study.2022Journal of healthcare engineeringFree full text
  44. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis.2022Scientific reportsFree full text
  45. Genotyping Helicobacter pylori antibiotic resistance and virulence-associated genes in patients with gastric cancer in Wenzhou, China.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  46. Prognostic value of small mother against decapentaplegic expression in human gastric cancer.2021BioengineeredFree full text
  47. Value of muscle quality, strength and gait speed in supporting the predictive power of GLIM-defined malnutrition for postoperative outcomes in overweight patients with gastric cancer.2021Clinical nutrition (Edinburgh, Scotland)
  48. Influence of body composition, muscle strength, and physical performance on the postoperative complications and survival after radical gastrectomy for gastric cancer: A comprehensive analysis from a large-scale prospective study.2021Clinical nutrition (Edinburgh, Scotland)
  49. Sarcopenia is a predictive factor of poor quality of life and prognosis in patients after radical gastrectomy.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  50. The relationship between the GLIM-defined malnutrition, body composition and functional parameters, and clinical outcomes in elderly patients undergoing radical gastrectomy for gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  51. Patterns of immune infiltration in gastric cancer and their clinical significance.2021Japanese journal of clinical oncology
  52. Identification of lncRNA-associated competing endogenous RNA networks for occurrence and prognosis of gastric carcinoma.2021Journal of clinical laboratory analysisFree full text
  53. C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression.2021Journal of experimental & clinical cancer research : CRFree full text
  54. Laparoscopic versus open resection for elderly patients with gastric cancer: a double-center study with propensity score matching method.2021Langenbeck's archives of surgery
  55. Measurement of muscle quantity/quality has additional predictive value for postoperative complications and long-term survival after gastrectomy for gastric cancer in patients with probable sarcopenia as defined by the new EWGSOP2 consensus:2021Nutrition (Burbank, Los Angeles County, Calif.)
Chinese-language papers (not in the count)1
  1. [Application of right-opening single flap valvuloplasty based on tubular stomach in gastrointestinal reconstruction after laparoscopic proximal gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status10
  1. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT07828899Lead sponsorN/AStart 2026-10
  2. Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic CancerNot yet recruitingNCT07394205Lead sponsorEarly phase 1Start 2026-09
  3. Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled TrialRecruitingNCT07586384Lead sponsorN/AStart 2025-11
  4. Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric CarcinomaCompletedNCT01711242Lead (inferred)Phase 2Start 2012-01
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  6. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  7. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  8. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  9. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  10. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

11 hospitals in Wenzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

2 hospitals in Wenzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Wenzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 442025

2 hospitals in Wenzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  2. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  3. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  4. Recruiting
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06520176

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou

  5. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  6. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  7. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  8. Recruiting
    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05594797

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou

  9. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  10. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskCAR-T & cell therapy

Over half of these papers are lab or animal studies.

Papers it led6
  1. Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation.2025Cancer immunology, immunotherapy : CIIFree full text
  2. Genetic association between coffee consumption and multiple myeloma mediated by plasma metabolites: a Mendelian randomization study.2025Food & function
  3. Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.2025Frontiers in immunologyFree full text
  4. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.2025Frontiers in public healthFree full text
  5. Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.2023Clinical lymphoma, myeloma & leukemia
Chinese-language papers (not in the count)1
  1. [Toxicity Management and Efficacy Evaluation of BCMA-CART in the Treatment of Relapsed and Refractory Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status26
  1. Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsStatus unknownNCT03302403Lead (inferred)N/AStart 2017-12
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  3. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  5. Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsRecruitingNCT06520176Study sitePhase 3Start 2024-08
  6. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  7. Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MMRecruitingNCT05594797Study sitePhase 2Start 2022-07
  8. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  9. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  10. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  11. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  12. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Study sitePhase 1Start 2025-05
  13. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  14. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  15. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  16. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  17. A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Study sitePhase 1Start 2023-06
  18. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsStatus unknownNCT05646758Study sitePhase 1Start 2023-03
  19. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05376345Study sitePhase 1Start 2022-09
  20. Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingNCT05317416Study sitePhase 3Start 2022-03
  21. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  22. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  23. Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple MyelomaStatus unknownNCT04003168Study sitePhase 1Start 2019-07
  24. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  25. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  26. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Wenzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPhiladelphia chromosome & genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Wenzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Wenzhou for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Analysis of genetic variant in a Chinese pedigree with hereditary factor VIII deficiency].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 5 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

1 hospital in Wenzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisRelapse preventionAcute attack treatment
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

1 hospital in Wenzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesBiologic & complement drugsAntibodies & diagnosisStandard immunotherapy
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Wenzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

4 hospitals in Wenzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led5
  1. Decoding tamoxifen on idiopathic pulmonary fibrosis: integrating network toxicology and multi-omics.2026International journal of surgery (London, England)
  2. Fibrotic extracellular matrix microenvironment induces alveolar type II epithelial cell senescence via integrin-β1/FAK/YAP signaling pathway.2025International immunopharmacology
  3. Demethyleneberberine ameliorates pulmonary fibrosis by inhibiting the NLRP3 inflammasome and the epithelial-mesenchymal transition.2025International immunopharmacology
  4. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.2024Lipids in health and disease
  5. WSB1, a Hypoxia-Inducible E3 Ligase, Promotes Myofibroblast Accumulation and Attenuates Alveolar Epithelial Regeneration in Mouse Lung Fibrosis.2024The American journal of pathology
Earlier papers (2016–2020)1
  1. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis.2019Nature communications
All its trials on ClinicalTrials.gov, any status3
  1. Anlotinib Capsules in the Treatment for IPF/PF-ILDsActive, not recruitingNCT05828953Lead sponsorPhase 2Start 2021-09
  2. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

2 hospitals in Wenzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Wenzhou for Behçet disease139 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Unveiling the Reason for Syncope Associated With Cardiac Nodules.2025Pacing and clinical electrophysiology : PACE
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 1120242025: 112025

5 hospitals in Wenzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led6
  1. Impact of intrarenal arterial lesions on prognosis of IgA nephropathy: insights from a retrospective cohort study.2025Renal failure
  2. An enhanced machine learning approach for effective prediction of IgA nephropathy patients with severe proteinuria based on clinical data.2024Computers in biology and medicine
  3. Clinical Significance of Persistent Hematuria Degrees in Primary IgA Nephropathy: A Propensity Score-Matched Analysis of a 10-Year Follow-Up Cohort.2023American journal of nephrology
  4. Clinical significance of intrarenal vascular lesions in non-hypertensive patients with IgA nephropathy.2023Journal of nephrology
  5. Clinical significance of massive proteinuria in primary IgA nephropathy with and without nephrotic syndrome: a single center cohort study.2023Renal failure
  6. Clinicopathological and prognostic study of IgA-dominant postinfectious glomerulonephritis.2021BMC nephrology
Chinese-language papers (not in the count)1
  1. [Progress in IgA-dominant infection-related glomerulonephritis].2023Zhonghua nei ke za zhi
Earlier papers (2016–2020)5
  1. Association between lifestyle, gender and risk for developing end-stage renal failure in IgA nephropathy: a case-control study within 10 years.2019Renal failure
  2. Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study.2018Human pathology
  3. Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.2018Immunologic research
  4. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.2017BMC nephrology
  5. Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy.2017Scientific reports
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wenzhou for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Wenzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wenzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Wenzhou for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. A neonate with dyspnoea.2016BMJ (Clinical research ed.)

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Wenzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

温州医科大学附属第一医院

First Affiliated Hospital of Wenzhou Medical University

温州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Affiliated Hospital of Wenzhou Medical University Wenzhou; First affiliated hospital of Wenzhou medical University; First Affiliated Hospital of Wenzhou Medical College; First Affiliated Hospital of Wenzhou Medical Uinversity; First Provincial Wenzhou Hospital of Zhejiang

Suggest a correctionDownload the data